Compare AdaptHealth Corp (AHCO) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AdaptHealth Corp vs 22nd Century Group Inc — how do they compare? AdaptHealth Corp trades at $10.04 (market cap $1.38B), while 22nd Century Group Inc trades at $4.16 (market cap $1.48M). The key difference: AdaptHealth Corp is far larger — about 932.4× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| AHCO | XXII | |
|---|---|---|
Market Cap | $1.38B | $1.48M |
Sector | Health | Technology |
52-Week High | $13.38 | $2.04K |
52-Week Low | $8.68 | $3.90 |
Enterprise Value | $3.33B | -$6.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
XXII trades at $4.28, up 6.73% in the last session, amid a bearish technical outlook. The company reported a net loss of $5.05M on $7.05M revenue in 2025, with negative profitability margins. Recent news highlights expansion of its VLN reduced-nicotine cigarettes into California and New York, aiming to capture market share. A 20:1 reverse stock split was executed on June 12, 2026, to adjust the share structure.
The outlook remains speculative with high execution risk; analyst consensus is 75% buy but fundamentals show deep losses. Key risks include sustained negative cash flow, regulatory hurdles for tobacco products, and reliance on financing. Upside depends on successful commercialization of VLN products and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
